ABSTRACT
Introduction This chapter reviews some of the review period’s advances in the mechanisms behind the anti-atherosclerotic functions of high-density lipoprotein (HDL). It includes, for the first time, publications on the adenosine triphosphate (ATP)-binding cassette transporter Al (ABCA1) receptor, which appears to be central to the process of reverse cholesterol transport (RCT), the first, as far as I am aware, human trial of a compound specifically designed to raise HDL and a novel therapeutic approach to decreasing atherosclerosis.
